Dual Diagnosis vs Co-Occurring Disorders: Understanding the Differences

Psychotic conditions, such as schizophrenia and bipolar disorder, can be difficult to manage without proper treatment and support. Unfortunately, these conditions can often appear during adolescence and can be misunderstood and stigmatized, making it challenging for adolescents to seek help. If you or someone you know is struggling with their mental health, it’s important to understand the symptoms of psychosis and the treatment options that are available to you.

In this blog, we will explore common misconceptions surrounding psychotic disorders, symptoms of these conditions, coping strategies, the importance of medication and therapy, and how to find an adolescent mental health clinic near you.

‍

Understanding the Symptoms of Psychotic Disorders

Psychotic conditions in adolescents can manifest in a variety of ways. Symptoms may include hallucinations, delusions, disorganized speech or behavior, and difficulty with thinking or concentration. Some adolescents with psychotic disorders may also experience mood disturbances, such as depression or mania. These symptoms can be very distressing and can interfere with daily life and the ability to care for oneself. This highlights the importance of accessing care for psychosis as early as possible.

‍

Coping Strategies for Living with Psychotic Disorders

Living with psychosis can be challenging, but there are many coping strategies that can help. One of the most important things is to maintain a routine and a sense of structure in one’s daily life. This can include things like setting a regular sleep schedule, eating nutritious meals, and engaging in meaningful activities. It’s also important to have a support network of family, friends, or healthcare professionals who can offer emotional support and practical assistance, when needed.

‍

The Importance of Medication and Therapy in Managing Psychotic Disorders

Medication and therapy are essential components of managing adolescent psychotic disorders. Medications can help alleviate symptoms and improve overall quality of life, but finding the right medication and dosage can take time and adjustments may be required before landing on the right medication regimen. Therapy, such as cognitive behavioral therapy or psychoeducation, can help adolescents learn coping strategies, improve social skills, and manage symptoms. This highlights the importance of finding a mental health clinic that provides specialized treatment for adolescent mental health.

‍

Misconceptions and Stigmas Surrounding Psychotic Disorders

Adolescents with psychotic disorders often face discrimination, fear, and prejudice due to common misconceptions surrounding these conditions. One of the most prevalent stigmas is the belief that people with psychotic conditions are violent or dangerous. In fact, research has shown that when treated, adolescents with psychotic disorders are more likely to be victims of violence than perpetrators. Other misconceptions include the idea that adolescents with these conditions are lazy or lack motivation, or that they are unable to function in society. These misunderstandings are untrue and many people with psychosis recover and go on to live rich and fulfilling lives.

‍

Finding an Adolescent Mental Health Clinic Near You

Finding an adolescent mental health clinic near you is crucial for adolescents living with psychotic conditions. A clinic like Amae Health that specializes in psychosis, schizophrenia and bipolar disorder can provide tailored treatment and support to help manage symptoms of these conditions and improve overall quality of life. It’s important to connect with others who understand what you’re going through and can offer empathy, advice, and encouragement.

In summary, if you or someone you know is in need of care, it’s important to take action. At Amae Health, we’re ready to help and can help you get back on track with life. We can be reached by email at hello@amaehealth.com. By understanding the symptoms and finding an adolescent mental health clinic that provides specialized treatment, individuals with psychotic conditions can lead fulfilling and meaningful lives.

‍

If you are comparing TMS, ketamine, and Spravato for depression, you have probably reached the point where standard antidepressants have not done enough. All three are evidence-based options for treatment-resistant depression, and beyond that they have little in common. TMS is a course of magnetic stimulation delivered while you sit awake in a chair. Ketamine is an anesthetic given by IV, used off-label for depression. Spravato is a nasal spray made from esketamine, one of the two mirror-image forms that make up ketamine, with its own FDA approval and its own rulebook.

‍

None of the three is universally better. They differ in mechanism, speed, setting, and monitoring, and the right one depends on your clinical history and how you respond. Treatment-resistant depression generally means depression that has not adequately improved after at least two antidepressants taken at a proper dose for long enough, and that is the group where all three are most often used.

What Is TMS?

Transcranial magnetic stimulation uses a coil placed against the scalp to deliver focused magnetic pulses to the left dorsolateral prefrontal cortex, a region involved in mood regulation. The FDA first cleared TMS for major depressive disorder in 2008, according to the National Institute of Mental Health. It is delivered in an office, with no anesthesia and no medication.

‍

Our standard TMS course runs 20 to 30 daily sessions over four to six weeks, each 30 to 40 minutes long. You stay awake throughout and drive yourself home afterward. In real-world outcome data from 42 U.S. practices, more than half of patients with medication-resistant depression responded to a standard course, and more than a third reached remission.

What Is Ketamine Therapy?

Ketamine has been an FDA-approved anesthetic since 1970. Its use for depression is off-label: prescribed for a purpose the FDA has not formally approved, which is legal and common in medicine but leaves the safeguards less standardized. It is usually given as an IV infusion in a monitored clinic, as a series of sessions over a few weeks.

‍

Ketamine blocks the NMDA receptor, a glutamate receptor, rather than acting on serotonin like standard antidepressants, and that difference is thought to explain its speed. In a landmark 2006 trial, 18 people with treatment-resistant depression received a single infusion of 0.5 mg/kg, and their symptoms improved significantly within 110 minutes. By the next day, 71% had responded and 29% were in remission. One week later, 35% still met the response threshold. Rapid, real, and often short-lived.

‍

The catch is in the monitoring. Ketamine causes dissociation, a sense of detachment from your body or surroundings, plus sedation and blood pressure rises during and after the infusion, so you are observed until those effects pass and cannot drive that day. In a 2017 consensus statement in JAMA Psychiatry, an American Psychiatric Association task force found the evidence for rapid antidepressant effects convincing but the studies small, the longer-term efficacy data lacking, and the safety data on repeated dosing limited.

What Is Spravato (Esketamine)?

Ketamine is a mixture of two mirror-image molecules. Spravato is esketamine, one of those two, delivered as a nasal spray. Unlike IV ketamine, it has FDA approval for depression. The original approval came in March 2019 for treatment-resistant depression alongside an oral antidepressant, a second indication followed for adults with major depressive disorder and acute suicidal thoughts or behavior, and in January 2025 the FDA approved Spravato as a standalone monotherapy for treatment-resistant depression, with no oral antidepressant required, per the current prescribing information.

‍

That approval comes with a rulebook. Spravato can only be given at a setting certified under a Risk Evaluation and Mitigation Strategy (REMS) program: you take the spray under supervision, you are monitored for at least two hours before an assessment clears you to leave, and you cannot drive until the next day after a restful sleep. Its label carries a boxed warning for sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors in younger patients.

‍

So is Spravato the same as ketamine? Related, not identical: same molecular family, same receptor, similar rapid onset and dissociative effects, but a different route, a formal FDA indication, and mandatory monitoring rules that off-label ketamine does not carry. For most people comparing TMS vs Spravato, those rules and insurance coverage are the practical differences that matter.

TMS vs Ketamine vs Spravato: Side-by-Side Comparison

Onset and Duration of Effect

Speed is the clearest dividing line. TMS builds gradually, and many people do not notice a clear change until the second or third week or later. Ketamine and Spravato can shift symptoms within hours to days.

‍

Speed and staying power are different things. Ketamine's effect after a single infusion often fades within a week or two, which is why it is given as a series with maintenance dosing. Spravato starts at twice a week and tapers, with the need for continued treatment reassessed along the way. Research on durability is still developing for all three, and none should be described as permanent.

Side Effects and Safety Considerations

TMS side effects are local and short-lived: scalp discomfort where the coil sits, headache, and sometimes brief lightheadedness or facial muscle twitching during the pulses. These usually settle within the first week, and because nothing enters the bloodstream there is no weight gain, sexual dysfunction, or sedation. Seizure is the one serious risk, exceedingly rare, and TMS is not used in people with a seizure history, metal in the head, or implanted electronic devices.

‍

Ketamine and Spravato share a different profile. The most common reactions to Spravato in trials were dissociation, dizziness, nausea, sedation, vertigo, numbness, anxiety, lethargy, increased blood pressure, vomiting, feeling drunk, and headache. Those effects peak in the hours after dosing, which is what the monitoring window is for, and both drugs carry a potential for misuse that shapes who is a candidate. Each option has its own screening, and a contraindication to one does not rule out the others.

Cost and Insurance

For TMS, most commercial insurers cover treatment for major depressive disorder once eligibility criteria are met, typically a confirmed diagnosis and documented antidepressant trials without adequate relief. Prior authorization is standard. For TMS we take all commercial insurance plans, cash pay is available, and authorization is something our intake team manages for you.

‍

Spravato is more commonly covered than off-label ketamine because it has an FDA indication insurers can write criteria around, though prior authorization and documentation of failed antidepressant trials are typically required. Ketamine infusion coverage varies widely, and many clinics are self-pay. Published cost estimates vary so much by dose, frequency, and insurance status that a single dollar figure would mislead; ask each provider and your insurer directly.

Can These Treatments Be Combined?

Sometimes, and the research is early. A 2024 systematic review found six published studies on combining TMS with ketamine, mostly case reports plus one retrospective review and one small pilot, and reported substantial and sustained improvement with generally mild side effects. The authors also said the designs were too varied and the samples too small for firm conclusions, and called for randomized trials.

‍

In practice, TMS and Spravato are sometimes used one after the other. Combining any of these is a clinical judgment a psychiatrist makes from your history, not a general recommendation, and the more common pattern is to use one, assess the response, then decide.

Choosing Between Them: What Influences the Decision

A psychiatrist weighing these options usually works through a short list:

‍

• Treatment history. Which antidepressants, at what doses, for how long, and whether psychotherapy has been tried.
• How urgently relief is needed. When symptoms are severe or suicidal thoughts are present, a faster-acting option may take priority, alongside care for suicidal thoughts.
• Tolerance for the experience. Dissociation and a two-hour monitored window, versus a daily half-hour appointment for several weeks with no drug effects.
• Practical constraints. Whether you can get to daily sessions, whether someone can drive you home after Spravato or ketamine, and what your insurance will authorize.
• Health factors. Seizure history, metal implants, blood pressure, and any history of substance misuse each rule options in or out.
• What else is in place. Any of the three works better inside ongoing psychiatric care and therapy than as a standalone fix.

Making the Decision With an Integrated Care Team

TMS, ketamine, and Spravato are tools, and tools do their best work inside a plan: a psychiatrist who knows your history, a therapist working alongside the biological treatment, and a team that notices when the plan needs to change.

‍

That is how we work. At Amae, our one-team care model combines psychiatry, therapy, primary care, and peer support, and TMS and Spravato are available through our Los Angeles and Bay Area clinics as part of that care. If you have been through the antidepressant cycle and want a clear, unhurried look at what comes next, talk with an Amae psychiatrist about your options. If you are in crisis or thinking about suicide, call or text 988 now.

Frequently Asked Questions

What is the difference between TMS and ketamine for depression?

TMS stimulates the brain with magnetic pulses over a course of daily outpatient sessions, with no drug, no sedation, and no monitoring afterward. Ketamine is a medication that acts on NMDA receptors, given by infusion or, as esketamine, by nasal spray, with monitored sedation and dissociation and often faster but shorter-lived effects.

Is Spravato the same as ketamine?

Related but not identical. Spravato is esketamine, the S-enantiomer of the ketamine molecule, delivered as an FDA-approved nasal spray under a required monitoring program. Ketamine infusions use the full ketamine compound and are prescribed off-label for depression, without an FDA indication for that use.

Is Spravato only approved with an antidepressant?

Not anymore. The original 2019 approval was for use alongside an oral antidepressant, and in January 2025 the FDA also approved Spravato as a standalone monotherapy for adults with treatment-resistant depression. Whether it is used alone or with an antidepressant is a decision your psychiatrist makes based on your situation.

Which works faster, TMS or Spravato?

Spravato. Esketamine and ketamine can produce symptom change within hours to days, while TMS builds gradually across a four-to-six-week course. Faster onset does not mean more durable improvement, and both durability and side effects belong in the comparison.

Can TMS and Spravato be used together?

Sometimes, as a clinical decision made with a psychiatrist based on your individual history. Both can be part of a broader treatment-resistant depression plan alongside medication and therapy, and the evidence on combining them is still early.

Is ketamine or Spravato covered by insurance?

Spravato is more commonly covered, because it has an FDA indication insurers can build criteria around, though prior authorization and proof of failed antidepressant trials are usually required. Coverage for off-label ketamine infusions varies widely and is often self-pay. Confirm with the provider and your insurer before starting.

‍

Citations

1. National Institute of Mental Health. Brain Stimulation Therapies. https://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies
2. Carpenter LL, Janicak PG, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depression and Anxiety. 2012. https://pubmed.ncbi.nlm.nih.gov/22689344/
3. Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry. 2006. https://pubmed.ncbi.nlm.nih.gov/16894061/
4. Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017. https://pubmed.ncbi.nlm.nih.gov/28249076/
5. U.S. Food and Drug Administration. Drugs@FDA: SPRAVATO (esketamine), NDA 211243, approval history. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211243
6. U.S. Food and Drug Administration. SPRAVATO (esketamine) nasal spray prescribing information, revised January 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf
7. Arubuolawe OO, Folorunsho IL, Busari AK, et al. Combination of transcranial magnetic stimulation and ketamine in treatment-resistant depression: a systematic review. Cureus. 2024. https://pubmed.ncbi.nlm.nih.gov/39156335/
8. 988 Suicide and Crisis Lifeline. https://988lifeline.org

‍

A schizophrenia diagnosis arrives to a person in a small room, and rearranges things without asking — the way a conversation feels, the way a plan for next year suddenly needs rewriting, the way someone you love looks at you and you can't quite tell what they're thinking anymore. Most of what you'll read about schizophrenia treatment options is either clinical to the point of cold, or optimistic in a way that skips the hard parts. 

Schizophrenia is a chronic condition. In 2026, it is also named one of the most treatable severe mental illnesses in psychiatry. The medications have quietly changed over the last two years, with the care models changing even faster. And the question clinicians now ask (is this person living a life they recognize as their own?) is a better question than the one psychiatry asked a generation ago.

This is a guide to what schizophrenia treatment actually looks like now.

What "Treatment" Means for Schizophrenia in 2026

For most of psychiatry's history, treating schizophrenia meant turning down the volume on hallucinations and delusions and hoping everything else would hold. Consequently, it often didn't. The older medications were blunt instruments — they could quiet the psychosis while leaving a person sedated, emotionally flat, and unable to concentrate. A patient could be symptom-free on paper and still lose their apartment, their job, and their social world, not because the illness had won, but because the treatment had taken too much with it.

That old goal has been replaced.

The modern target is functional recovery: the ability to live a connected, productive life, be it work or school. Rebuilding the relationships that came apart during the acute phase. Living on your own terms. Functional recovery is not the same as symptom elimination. Some of the people who reach it still hear voices, and some of the people with zero symptoms can't hold a routine. What functional recovery actually requires, almost without exception, is a care plan that treats medication, therapy, physical health, and social support as one whole problem instead of four.

Pharmacological Breakthroughs: A New Era of Medication

Medication is the floor of schizophrenia treatment, not the ceiling. For about 40 years, that floor was built of one material: antipsychotics that bind dopamine D2 receptors and block the signal. That is still the starting point for most patients in 2026. What has quietly changed is the field, which now has options that were not there two years ago.

Second-Generation Antipsychotics: The Current Standard

Risperidone, olanzapine, aripiprazole, paliperidone, quetiapine. Those are the names that will likely appear first in any conversation with a psychiatrist. They're called "second-generation" or "atypical" antipsychotics because together, they work on dopamine and serotonin, producing a more favorable profile for negative symptoms and cognitive effects than the drugs that came before them.

They work. They also come at a cost.

The trade-off is metabolic. Weight gain. Elevated blood sugar. Shifts in lipid panels that, untracked, add up to real cardiovascular risk over time. A care team that prescribes these medications without monitoring the body is doing half the job. Metabolic monitoring is not optional.

The Non-Dopaminergic Revolution: Cobenfy and Muscarinic Agonists

In September 2024, something happened in schizophrenia pharmacology for the first time in about 35 years. The FDA approved xanomeline-trospium (Cobenfy, formerly known as KarXT), and the mechanism was not a variation on the dopamine theme. Cobenfy works on muscarinic receptors (specifically the M1 and M4 subtypes), meaning the biological pathway it acts on is different in kind, not just in detail (Yale Medicine).

Here is why that matters.

Roughly one-third of patients don't respond adequately to dopamine-based medications. The metabolic and movement-related side effects of the older drugs are also downstream of dopamine blockade. Cobenfy doesn't block dopamine, which is why early trials suggest it may avoid some of that side effect profile.

Long-term data is still accumulating. For now, the field has its first new mechanism in a generation.

Long-Acting Injectables: Reducing the Daily Burden

Long-acting injectable antipsychotics, or LAIs, deliver a single dose that lasts weeks or even months. For patients whose relapses have traced back to missed pills, that is a meaningful shift.

The evidence has caught up with the intuition. A 2022 network meta-analysis in World Psychiatry pooled 92 randomized trials and 22,645 participants and found that LAIs hold up against daily oral antipsychotics in preventing relapse (Ostuzzi et al., 2022). Real-world studies of US Medicare patients have shown LAIs are associated with lower rates of psychiatric hospitalization and treatment discontinuation.

LAIs are not right for every patient. Some people find meaning in the daily ritual of a pill. Some have had painful experiences with injections. The right answer comes out of a real conversation with a psychiatrist who has the patient's history in front of them.

Models of Care: Why the Environment Matters

The same medication can produce very different outcomes depending on how it is delivered. Two patients on the same dose of the same drug can end up in very different places a year later. The difference is usually the system around them.

Coordinated Specialty Care (CSC)

In 2026, coordinated Specialty Care is the standard for early psychosis.It is also one of the clearest examples in psychiatry of a care model producing better outcomes than a new drug would. The American Psychiatric Association formally endorsed it in its 2020 practice guideline (APA Practice Guideline for the Treatment of Patients With Schizophrenia), and it came out of the NIMH RAISE research initiative.

The model is a single team of clinicians working from one plan: medication management, individual therapy, supported employment and education, family education, and case management that actually happens, rather than getting sent to five different offices on five different days.

The data is strong. In the NIMH RAISE Early Treatment Program, patients who received CSC had hospitalization rates of 23% compared with 44% in usual community care (NIMH: Team-based Treatment is Better for First Episode Psychosis). They were also more likely to stay in school or employment and experienced greater improvement in symptoms, interpersonal relationships, and quality of life (Kane et al., American Journal of Psychiatry, 2016).

That is a halving of hospitalization risk, produced by a care model rather than a new molecule.

CSC was built for early psychosis. For patients further along in treatment, other models fit better.

Integrated Outpatient Care for Severe Mental Illness

For patients past the first-episode window, integrated outpatient care takes the same principle as CSC and adapts it for the long haul. The model brings psychiatrists, therapists, primary care physicians, dietitians, health coaches, peer mentors, and clinical care coordinators under one roof, working from a single shared plan.

The problem it solves is fragmentation. In the usual picture, a patient has a psychiatrist at one office, a therapist at another, a primary care provider at a third, and if case management exists at all, it runs on lost email attachments. Small things become crises. Crises become hospitalizations. Hospitalizations become the next relapse.

But it doesn't have to work that way.

This is the model our integrated outpatient clinics are built on. We see adults 18 and older. Our care team is designed so that mental health, physical health, and everyday function are handled in the same place, by people who talk to each other. The patient is not the one running the coordination.

Crisis Services and Long-Term Stability

Crisis services are not long-term care, and long-term care is not crisis services. Inpatient hospitalization exists to keep people safe when symptoms are acute. It is essential, and it saves lives. But it is not designed to produce long-term stability, and the handoff from inpatient to outpatient is the highest-risk period for readmission. That handoff is where integrated outpatient care earns its keep.

Evidence-Based Psychosocial Interventions

Medication does one job well. It quiets the biology. Everything else is outside what a pill can do: how a person thinks about what is happening to them, how they rebuild relationships that came apart during the acute phase, how they get back into work or school.

That is where psychosocial interventions come in.

Cognitive Behavioral Therapy for Psychosis (CBTp)

CBT for Psychosis, usually shortened to CBTp, is not standard CBT with a few tweaks. It is a specialized protocol built from the ground up for people who hear voices, hold persistent unusual beliefs, or are trying to function while symptoms are still present. The APA practice guideline gives CBTp a 1B rating, which translates roughly to "the evidence is strong and clinicians should offer this" (APA Practice Guideline, 2020).

What CBTp actually does in a session is teach specific skills. Reality testing. Cognitive distancing from distressing voices. Stress-reduction techniques for the moments when symptoms spike. Coping strategies for persistent delusions that have not responded fully to medication. The goal is not to eliminate the symptoms. It is to change the relationship a person has with them.

Social Skills and Vocational Training

Skills erode during acute episodes. A patient who was holding a job six months ago and had friends two years ago can come back from a hospitalization and find that the conversational rhythm, the workplace reflexes, and the social scaffolding are all gone. Not permanently. Just not where they left them.

Structured social skills training is what it sounds like: deliberate practice. Starting conversations. Reading a room at work. Managing conflict without escalation. Re-entering relationships that went quiet during the acute phase. Supported employment programs pair these skills with real job coaching, and the evidence is that they help people get and keep work when traditional vocational rehabilitation has not.

Cognitive Remediation

Hallucinations and mood can stabilize while the harder, quieter symptoms persist: forgetting appointments, losing the thread of a conversation, struggling to plan a week. These are the symptoms that sit between "stable" and "back to a life I recognize." For many patients, they are what actually prevents the return to work or school.

Cognitive remediation is structured training for those skills. Memory exercises. Attention work. Executive function practice. The programs are not new, but they are one of the most underprescribed interventions in this space. They will not cure cognitive symptoms, but they can meaningfully improve day-to-day function.

The Role of Family and Community Support

No one recovers from schizophrenia alone. That is not a sentimental claim, but a finding that has been reproduced in study after study over several decades.

Family psychoeducation is one of the most consistently supported non-medication interventions in the books. The idea is simple: when the people a patient lives with understand what schizophrenia is, what the medications do, and how to communicate in hard moments, relapse rates drop. A concept in the research called "expressed emotion" describes a household climate marked by high levels of criticism, hostility, or emotional over-involvement. When that climate softens, relapse rates soften with it. Nothing about this says families cause schizophrenia. They don't. But the environment in which treatment either catches or slips is incredibly important.

Community reintegration carries the same weight. A stable apartment. A part-time job, even a small one. Peer support groups. A faith community if that fits. Friendships that survive the acute phase. These are not "lifestyle" factors that sit outside treatment. They are the treatment. A patient with housing and a routine has a very different clinical trajectory from the same patient without them.

How to Choose Among Schizophrenia Treatment Options

The question families ask us is almost never "should we get treatment." It is "how do we pick the right place." A few things matter more than the rest in that decision.

Start with the intake. A good assessment is not a form that takes 20 minutes to fill out. It is a conversation that covers psychiatric history, medication history and response, current symptoms, physical health, substance use, the home situation, and what the patient actually wants out of treatment. If the intake is structured as a checklist, the treatment plan will be too.

Ask how the team communicates. Is there a dedicated case manager? Does the psychiatrist read the therapist's notes? Is metabolic monitoring built into the schedule? Is family involvement standard? Are outcomes tracked? These are the questions we built our care model to answer, and a clinic that stumbles on them is worth a second look.

Insist on shared decision-making. A patient is a participant in their treatment, not a recipient of it. A good clinician lays out the trade-offs of each medication in plain language, listens to what the patient wants, and makes decisions alongside them. A clinician who rushes that or waves it off is telling you something.

Frequently Asked Questions

Q: Can schizophrenia be cured?

Not cured in the traditional sense. Schizophrenia is managed, which is a word that sounds smaller than it is. "Managed" in 2026 can mean living for decades with minimal disruption, working, keeping relationships, and needing medical care the way a person with diabetes does. Functional recovery is achievable for a meaningful number of patients, though not all.

Q: What happens if I stop taking my medication?

The risk of relapse rises sharply. What makes stopping tricky is the delay. Many people who discontinue antipsychotic medication feel fine for weeks, sometimes months, before symptoms return. That gap is long enough to conclude the medication wasn't necessary, and then to be caught off guard when symptoms do come back. Talk to your prescriber before making any changes.

Q: Are there natural treatments for schizophrenia?

Sleep, exercise, nutrition, and stress management support mental health and matter for anyone living with schizophrenia. They are not a substitute for medical treatment. If something is marketed as a "natural cure" for schizophrenia, that is a reason to stop reading. Supplements, herbs, and alternative therapies have not been shown to treat the underlying biology of the condition. Some interact with prescribed medications in ways that can be dangerous.

Q: How do I help a loved one who refuses treatment?

This is the question we hear most from families, and it is the hardest one. A few things help:

• Anosognosia, a lack of awareness of one's illness, is itself a symptom of schizophrenia. It is not denial. Understanding the difference can change how you approach the conversation.
• The LEAP method (Listen, Empathize, Agree, Partner), developed by Dr. Xavier Amador, was built for exactly these situations.
• NAMI's Family-to-Family programs teach communication skills and connect families with others walking the same path.
• In an acute safety crisis, call 988, the Suicide and Crisis Lifeline, or your local mobile crisis team.

Moving Toward Functional Recovery

A schizophrenia diagnosis is a serious event. It is not a verdict.

The range of schizophrenia treatment options has meaningfully widened since 2024. New medications. New evidence about old medications. Care models with strong outcomes data. Psychosocial interventions that help with the parts of recovery medication cannot touch. The clinical goal has moved from quieting the biology to helping a person live a life they recognize as their own.

What most patients and families need is not a single treatment.

They need a team that treats the whole picture, which means symptoms, physical health, relationships, work, and function, as one problem instead of four.

If you or someone you love is living with schizophrenia, schizoaffective disorder, or a related condition, Amae Health is here to talk. Our care teams include psychiatrists, therapists, primary care providers, dietitians, health coaches, peer mentors, and clinical care coordinators, all working from one shared plan. We see adults 18 and older at our clinics in Los Angeles, Los Altos, San Mateo, Raleigh, New York, and Brooklyn. To start the conversation, request an intake appointment.

‍

Citations

1. 3 Things to Know About Cobenfy, Yale Medicine. Tier 4 (major academic medical center).
2. Ostuzzi et al., "Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants," World Psychiatry, 2022. Tier 1 (peer-reviewed).
3. Kane et al., "Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program," American Journal of Psychiatry, 2016. Tier 1 (peer-reviewed).
4. NIMH: Team-based Treatment is Better for First Episode Psychosis. Tier 2 (government).

The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, 2020. Tier 3 (professional association).